2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2018
Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation
Aghighi M, Theruvath AJ, Pareek A, Pisani LL, Alford R, Muehe AM, Sethi TK, Holdsworth SJ, Hazard FK, Gratzinger D, Luna-Fineman S, Advani R, Spunt SL, Daldrup-Link HE. Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. Clinical Cancer Research 2018, 24: 4110-4118. PMID: 29764855, PMCID: PMC6125171, DOI: 10.1158/1078-0432.ccr-18-0673.Peer-Reviewed Original ResearchConceptsBone sarcomasClinical trialsFerumoxytol-enhanced MRIImmune-targeted therapiesProspective clinical trialsYoung adult patientsDensity of CD68Biopsy/resectionClin Cancer ResTumor biopsy/resectionInstitutional review boardNoninvasive imaging techniquesPrecontrast scansTAM densityAdult patientsPilot patientsPediatric patientsPostcontrast MRIPostcontrast scansCancer immunotherapyMacrophage stainingTumor responseMRI 24Tumor groupMalignant tumors
2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis
Oke O, Sethi T, Goodman S, Phillips S, Decker I, Rubinstein S, Concepcion B, Horst S, Jagasia M, Kassim A, Harrell SL, Langone A, Lenihan D, Rawling KT, Slosky D, Cornell RF. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis. Transplantation And Cellular Therapy 2017, 23: 1473-1477. PMID: 28546074, DOI: 10.1016/j.bbmt.2017.05.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBortezomibFemaleHematopoietic Stem Cell TransplantationHumansImmunoglobulin Light-chain AmyloidosisInduction ChemotherapyMaleMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainProportional Hazards ModelsProteinuriaRetrospective StudiesStroke VolumeTransplantation, AutologousTreatment OutcomeConceptsAutologous hematopoietic cell transplantationProgression-free survivalTransplantation-related mortalityHematopoietic cell transplantationOverall survivalCT cohortLight chain amyloidosisCell transplantationLower brain natriuretic peptide levelsChain amyloidosisBrain natriuretic peptide levelsMedian progression-free survivalSuperior progression-free survivalBortezomib-based treatmentExperienced transplantation centersGood partial responseNatriuretic peptide levelsCohort of patientsMajority of patientsHigher ejection fractionEligible patientsInduction chemotherapyInduction therapyPartial responseEjection fraction
2016
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.
Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology 2016, 280: 905-15. PMID: 26982677, PMCID: PMC5006736, DOI: 10.1148/radiol.2016151301.Peer-Reviewed Original ResearchConceptsBasis of RECISTWorld Health OrganizationTherapeutic responseStandard of referenceOverall survivalClinical outcomesTumor responseTumor measurementsThree-dimensional tumor measurementsResponse Evaluation CriteriaPrimary tumor sizeLog-rank testKaplan-Meier plotsTherapeutic response assessmentInstitutional review boardTumor volume measurementsVolume measurementsPatient survivalRetrospective studyCox regressionTumor sizeGroup criteriaBland-Altman analysisEwing's sarcomaMedical Center